(VTRS) Viatris - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92556V1061

Prescription, Generic, Biosimilar, Complex-Dosage

Pharmaceuticals
Market Cap in USD: 14,731m

IPO / Inception: 2020-11-16
12m vs SPY: -6.66%

EPS (Earnings per Share)

EPS CAGR: -51.15%
EPS Trend: -72.0%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -3.76%
Rev. Trend: -83.2%

Last SUE: 2.32
Qual. Beats: 2

Dividends

Dividend Yield	4.98%
Yield on Cost 5y	3.39%
Yield CAGR 5y	9.82%
Payout Consistency	61.6%
Payout Ratio	20.6%

Risk via 5d forecast
Volatility	29.2%
Value at Risk 5%th	44.8%
Relative Tail Risk	-6.66%

Reward TTM
Sharpe Ratio	0.44
Alpha	-5.00
CAGR/Max DD	0.16

Character TTM
Hurst Exponent	0.481
Beta	0.809
Beta Downside	1.126

Drawdowns 3y
Max DD	45.02%
Mean DD	16.68%
Median DD	16.72%

Description: VTRS Viatris January 03, 2026

Viatris Inc. (NASDAQ: VTRS) is a global healthcare firm operating across North America, Europe, Greater China, Japan-Australia-New Zealand (JANZ), and emerging markets. It markets a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars covering therapeutic areas such as cardiovascular, CNS, diabetes, oncology, and respiratory diseases, and distributes through wholesalers, retail pharmacies, specialty and e-commerce channels.

Key recent metrics: Q4 2023 revenue of $2.3 billion, representing a 5% YoY increase driven by higher generic sales in the U.S.; adjusted EBITDA margin of ~12%; and a net debt-to-EBITDA ratio of 2.1×, indicating moderate leverage. Sector drivers include a projected 6% CAGR for the global generic drug market through 2028 and pricing pressure from payer reforms, which makes Viatris’s diversified geographic exposure and biosimilar pipeline (e.g., the BOTOX biosimilar partnership with Revance) strategically important.

For a deeper quantitative assessment, you may want to explore ValueRay’s detailed valuation metrics for VTRS.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-3.69b TTM) > 0 and > 6% of Revenue (6% = 847.5m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 18.32% (prev 25.22%; Δ -6.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 1.98b > Net Income -3.69b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.16b) change vs 12m ago -2.98% (target <= -2.0% for YES)

Gross Margin 36.07% (prev 39.90%; Δ -3.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.17% (prev 33.62%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.16 (EBITDA TTM -598.9m / Interest Expense TTM 471.9m) >= 6 (WARN >= 3)

Altman Z'' -0.23

(A) 0.07 = (Total Current Assets 9.95b - Total Current Liabilities 7.36b) / Total Assets 37.92b

(B) -0.00 = Retained Earnings (Balance) -48.2m / Total Assets 37.92b

(D) -0.12 = Book Value of Equity -2.75b / Total Liabilities 22.70b

Total Rating: -0.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.87

1. Piotroski 3.50pt

2. FCF Yield 5.65%

3. FCF Margin 11.32%

4. Debt/Equity 0.97

5. Debt/Ebitda -22.94

6. ROIC - WACC (= -16.11)%

7. RoE -22.69%

8. Rev. Trend -83.18%

9. EPS Trend -72.04%

What is the price of VTRS shares?

As of January 13, 2026, the stock is trading at USD 12.68 with a total of 5,841,790 shares traded.
Over the past week, the price has changed by +2.51%, over one month by +8.84%, over three months by +30.09% and over the past year by +12.92%.

Is VTRS a buy, sell or hold?

Viatris has received a consensus analysts rating of 3.44. Therefor, it is recommend to hold VTRS.

Strong Buy: 2
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the VTRS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	12.8	0.8%
Analysts Target Price	12.8	0.8%
ValueRay Target Price	14.4	13.7%

VTRS Fundamental Data Overview January 11, 2026

P/E Forward = 5.2083
P/S = 1.0429
P/B = 0.9658
P/EG = 0.1436
Beta = 0.792
Revenue TTM = 14.12b USD
EBIT TTM = -3.38b USD
EBITDA TTM = -598.9m USD
Long Term Debt = 12.49b USD (from longTermDebt, last quarter)
Short Term Debt = 2.06b USD (from shortTermDebt, last quarter)
Debt = 14.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.74b USD (from netDebt column, last quarter)
Enterprise Value = 28.29b USD (14.73b + Debt 14.72b - CCE 1.16b)
Interest Coverage Ratio = -7.16 (Ebit TTM -3.38b / Interest Expense TTM 471.9m)
EV/FCF = 17.69x (Enterprise Value 28.29b / FCF TTM 1.60b)
FCF Yield = 5.65% (FCF TTM 1.60b / Enterprise Value 28.29b)
FCF Margin = 11.32% (FCF TTM 1.60b / Revenue TTM 14.12b)
Net Margin = -26.13% (Net Income TTM -3.69b / Revenue TTM 14.12b)
Gross Margin = 36.07% ((Revenue TTM 14.12b - Cost of Revenue TTM 9.03b) / Revenue TTM)
Gross Margin QoQ = 36.83% (prev 37.21%)
Tobins Q-Ratio = 0.75 (Enterprise Value 28.29b / Total Assets 37.92b)
Interest Expense / Debt = 0.81% (Interest Expense 119.6m / Debt 14.72b)
Taxrate = -1.77% (negative due to tax credits) (11.0m / -623.2m)
NOPAT = -3.44b (EBIT -3.38b * (1 - -1.77%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.35 (Total Current Assets 9.95b / Total Current Liabilities 7.36b)
Debt / Equity = 0.97 (Debt 14.72b / totalStockholderEquity, last quarter 15.22b)
Debt / EBITDA = -22.94 (negative EBITDA) (Net Debt 13.74b / EBITDA -598.9m)
Debt / FCF = 8.59 (Net Debt 13.74b / FCF TTM 1.60b)
Total Stockholder Equity = 16.27b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.93% (Net Income -3.69b / Total Assets 37.92b)
RoE = -22.69% (Net Income TTM -3.69b / Total Stockholder Equity 16.27b)
RoCE = -11.74% (EBIT -3.38b / Capital Employed (Equity 16.27b + L.T.Debt 12.49b))
RoIC = -11.25% (negative operating profit) (NOPAT -3.44b / Invested Capital 30.55b)
WACC = 4.87% (E(14.73b)/V(29.45b) * Re(8.90%) + D(14.72b)/V(29.45b) * Rd(0.81%) * (1-Tc(-0.02)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.99%
[DCF Debug] Terminal Value 85.21% ; FCFF base≈1.72b ; Y1≈1.55b ; Y5≈1.33b
Fair Price DCF = 22.93 (EV 40.15b - Net Debt 13.74b = Equity 26.41b / Shares 1.15b; r=5.90% [WACC]; 5y FCF grow -12.37% → 2.90% )
EPS Correlation: -72.04 | EPS CAGR: -51.15% | SUE: -4.0 | # QB: 0
Revenue Correlation: -83.18 | Revenue CAGR: -3.76% | SUE: 2.32 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=2.46 | Chg30d=-0.003 | Revisions Net=+4 | Growth EPS=+6.6% | Growth Revenue=+1.3%

Additional Sources for VTRS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle